KWAR23, an anti-human SIRPα antibody, exhibits high-affinity binding to human SIRPα, inhibiting its interaction with CD47. Demonstrating antitumor activity, KWAR23 is efficacious in conjunction with tumor-opsonizing antibodies, making it a valuable agent for cancer immunotherapy research [1].

KWAR 23 (0-1 μM；4小时) 对人类中性粒细胞和巨噬细胞显示出抗肿瘤活性[1]。KWAR 23 诱导依赖于人类巨噬细胞的吞噬作用，作用于源自人类肿瘤的细胞系[1]。

KWAR23（腹腔注射；10 mg/kg；隔日给药；21天）在人源化SIRPA基因敲入的小鼠模型中显示出显著的抗肿瘤活性[1]。此化合物还能增强SRG小鼠中中性粒细胞和巨噬细胞的抗肿瘤功能[1]。